Saif, Areeba
Verbus, Emily A.
Sarvestani, Amber Leila
Teke, Martha E.
Lambdin, Jacob
Hernandez, Jonathan M.
Kirsch, David G.
Article History
Received: 19 October 2022
Accepted: 27 October 2022
First Online: 17 November 2022
Disclosures
: DGK has received research funding from XRAD Therapeutics, Bristol Myers Squibb, Varian Medical Systems, Merck Sharp and Dohme LLC. DGK owns stock and is on the scientific advisory board of Lumicell, Inc., which is commercializing intraoperative imaging technology. DGK is a cofounder of XRAD Therapeutics, which is developing radiosensitizers. The other co-authors report no conflicts of interest.